|
HS Code |
757590 |
| Name | 2,5-Pyrrolidinedione, 1,1'-[Ox ybis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci) |
| Molecular Formula | C12H14N2O8 |
| Molar Mass | 314.25 g/mol |
As an accredited 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 2,5 - Pyrrolidinedione, 1,1'-[Oxybis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci) in sealed container. |
| Shipping | 2,5 - Pyrrolidinedione compound is shipped with strict adherence to chemical safety regulations. It's carefully packaged to prevent spills and damage, transported in specialized containers suitable for its chemical nature, ensuring safe transit. |
| Storage | Store 2,5 - Pyrrolidinedione, 1,1'-[Oxobis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci) in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and contact with air, which could potentially lead to decomposition. Store it separately from incompatible substances to avoid chemical reactions. |
The addition sequence is engineered to suppress premature hydrolysis of the activated ester during scale-up from bench to 50 L single-use bioreactor assemblies. The diglycolate-based bis-NHS ester is dissolved in anhydrous acetonitrile (Karl Fischer titre ≤30 ppm) and metered at 0.8 mL/min via a peristaltic pump into a jacketed vessel holding the antibody-drug intermediate at 4.0 °C ±0.5 °C under laminar nitrogen overlay. The target drug-to-antibody ratio (DAR) of 3.6 is achieved with a crosslinker stoichiometry of 2.2 molar equivalents relative to the cytotoxic payload amine, with excess quenching by 50 mM glycine after a contact time not exceeding 90 seconds. Conjugate heterogeneity is monitored in real time by hydrophobic interaction chromatography (HIC) on a TSKgel Butyl-NPR column (4.6 mm I.D. × 100 mm) with mobile phase A: 1.5 M ammonium sulfate, 50 mM potassium phosphate, pH 7.0, and B: 50 mM potassium phosphate, pH 7.0 with 20% isopropanol. Process intermediates are held to the aggregate specification of ≤ 0.5% high-molecular-weight species by SEC-MALS before tangential flow filtration with a 30 kDa regenerated cellulose membrane concentrates the conjugate to 15 mg/mL. The terminal product is an aseptically filled lyophilized cake in a 10R Type I borosilicate glass vial with a label-claim DAR range of 3.2–4.0. Pharmacopoeial compliance for residual solvents follows USP <467> Option 2, with acetonitrile capped at 410 ppm and DMSO at ≤ 5000 ppm, while impurity profiling adheres to ICH Q6B guidelines for glycoconjugate characterization. Any nitrogen-blanketed intermediate held beyond 4 hours at 2–8 °C is subjected to subvisible particle testing per USP <787> using a light obscuration counter.What Engineering Controls Mitigate NHS Ester Hydrolysis During Continuous-Flow Immobilisation onto Carboxylated Magnetic Beads?When the diglycolate crosslinker is employed to coat 2.8 µm superparamagnetic iron oxide beads with a capture antibody for chemiluminescent immunoassay kits, the aqueous solubility limitation introduces a dimensionless Damköhler number constraint that dictates the microfluidic mixing geometry. A serpentine reactor channel with hydraulic diameter 0.5 mm and an in-line static mixer element at a Reynolds number of 180 produces a residence-time distribution where 92% of the fluid elements experience a contact time of 45 ± 3 seconds before the activated bead stream encounters a 200 mM ethanolamine, pH 8.5 quenching solution. The crosslinker is pre-activated onto the bead surface via EDC/sulfo-NHS chemistry at a density of 1.2 × 10⁴ NHS groups per µm², after which the bis-NHS diglycolate is introduced at a molar ratio of 0.8:1 relative to the surface NHS esters to form a semi-permanent spacer arm that resists nucleophilic displacement during storage in 50 mM MES, 0.1% BSA, pH 6.0 at 37 °C. Real-time process analytical technology (PAT) integration employs attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy with a diamond probe immersed in the flow cell, tracking the disappearance of the asymmetric carbonyl stretch at 1812 cm⁻¹ to hold the coupling efficiency within a 5% drift band. Conjugation yield is quantified offline by a ninhydrin-based free-amine assay referenced to a glycine standard curve (linear range 0.02–0.5 µmol/mL, R² >0.995). The final reagent is a homogeneous bead suspension in 10 mM Tris, 150 mM NaCl, 0.05% ProClin 950, pH 7.6, filled into 100 mL high-density polyethylene bottles and sterilized by gamma irradiation at 25 kGy. Design control documentation is maintained under ISO 13485:2016 Clause 7.3, and the product is registered as a component of a class B in vitro diagnostic medical device under EU IVDR 2017/746 Annex VIII, category 1.2.Surgeons handling hydrated gelatin-alginate interpenetrating networks require a crosslink density gradient that can be spatially decoupled from the UV-initiated radical density to prevent the stiffening modulus from deviating beyond 30 kPa at the tissue interface. The diglycolate bis-NHS ester is dissolved in a 20% w/w Pluronic F-127 chilled aqueous coprocessed with the polysaccharide phase at 2.0 °C before being coextruded through a 1.2 mm dual-lumen static mixer tip with the gelatin phase, where the crosslinker addition rate corresponds to 0.3 mmol NHS per gram of total protein. Gelation kinetics determined by oscillatory rheometry at 1 Hz frequency, 0.1% strain amplitude indicate a sol-gel transition at 14.8 ± 0.7 °C with a storage modulus plateau of 8.3 kPa for a 1.5 mm thick film intended for post-operative adhesion prevention. The process window is narrowed by the hydrolytic half-life of the terminal NHS group in unbuffered water at 25 °C, measured at 28 minutes by stopped-flow conductometry; any deviation in the residence time of the mixed precursor beyond 6 minutes results in a 17% reduction in the elastic component of the complex modulus, as corroborated by texture analysis of the cured film after 24 hours immersion in simulated peritoneal fluid at 37 °C. The aseptic processing stage requires endotoxin reduction by tangential flow filtration through a 100 kDa polyethersulfone cassette, targeting <0.06 EU/mg device per USP <161>. The final presentation is a sterile-packed pre-filled double-syringe applicator system with a polypropylene static mixing tip, validated for shelf stability at 2–8 °C for 18 months per ASTM F1980-21 accelerated aging using Arrhenius kinetics with Q₁₀ = 2.2. Biocompatibility evaluation follows ISO 10993-1:2018 endpoints for a surface-contacting, long-term implant: cytotoxicity (ISO 10993-5, agarose overlay), intracutaneous reactivity, and ASTM F756 hemolysis index (acceptance value <2%).
Lyophilized Protein-Micelle Crosslinking Monitored by Fluorometric Free Amine DepletionIn the manufacture of sub-100 nm protein-loaded polymeric micelles intended for passive tumour accumulation via the enhanced permeability and retention (EPR) effect, the diglycolate crosslinker functions as a core-stabilizing agent that covalently bridges adjacent lysine residues of the encapsulated therapeutic enzyme. The micelle shell is composed of a poly(ethylene glycol)-block-poly(ε-caprolactone) diblock copolymer (Mₙ 5kDa-b-3.5kDa) that is dissolved in tetrahydrofuran and nanoprecipitated into 10 mM HEPES, pH 7.4 containing the enzyme at 2.5 mg/mL. The crosslinker, predissolved in anhydrous dimethylformamide (0.5% v/v relative to the aqueous phase), is injected into the micelle suspension at a molar NHS-to-lysine ratio of 1.5:1, with the stirring speed maintained at 400 rpm in a glass-lined reactor. After 20 minutes of coupling, the percentage of free primary amines is reduced by 63% as quantified by an ortho-phthalaldehyde (OPA) fluorometric assay using excitation wavelength 340 nm and emission 455 nm, calibrated against a lysine standard in the range 0.01–0.8 mM. Crosslinked micelles are subjected to diafiltration with 10 volumes of sucrose-containing cryoprotectant solution across a 100 kDa polyethersulfone hollow-fiber module before lyophilization in a 24 m² shelf freeze-dryer with annealing at -10 °C for 4 hours. The terminal dosage form is a sterile lyophilized powder for injection that reconstitutes in < 30 seconds with Water for Injection to yield micelles with a polydispersity index (PDI) of 0.12 by dynamic light scattering. Quality specifications include endotoxin content ≤ 0.5 EU/mg and residual THF ≤ 720 ppm per ICH Q3C (Class 2 solvent), with the manufacturing suite operating under ISO 14644-1 Class 7 background and ISO 5 unidirectional-airflow filling zones.When Residual Solvating DMF Interferes with the Glass Transition of PLGA Microsphere ScaffoldsThe incorporation of the diglycolate linker into poly(lactic-co-glycolic acid) (PLGA, 50:50 lactide:glycolide, inherent viscosity 0.42 dL/g) microspheres via a solid-in-oil-in-water (S/O/W) double emulsion demands strict control over the organic internal phase composition to prevent plasticization that depresses the polymer Tg below 37 °C. The crosslinker is co-dissolved with the protein-loaded trehalose microparticles and PLGA in a mixture of dichloromethane and ethyl acetate (80:20 v/v), where residual dimethylformamide from the crosslinker stock must be kept below 0.2% v/v to avoid a Tg drop exceeding 4 °C, as measured by modulated differential scanning calorimetry (MDSC) at a heating ramp of 3 °C/min with a modulation amplitude of ±0.5 °C every 60 seconds. Microsphere formation uses an in-line Silverson rotor-stator homogenizer operated at 5000 rpm followed by solvent extraction in a 2% w/v polyvinyl alcohol (13–23 kDa, 87–89% hydrolyzed) continuous phase sparged with nitrogen. The crosslinker is present at 0.8 wt% relative to PLGA mass, creating a nominal crosslink density that reduces initial burst release from 28% to 9% in a 24-hour in vitro release study using PBS with 0.02% Tween 80 at 37 °C. Terminal sterilization is performed by gamma irradiation at 15 kGy on dry ice, and the final product is a vialed microsphere powder for reconstitution with a diluent syringe, forming an extended-release suspension with a label indication for monthly administration. Compendial testing aligns with Ph. Eur. 2.9.34 for bulk density and tapped density, and residual ethylene oxide post-sterilization is verified at ≤ 1 µg/g per ISO 10993-7:2008.
|
Competitive 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Property | Oxydiacetate bis‑NHS ester (this product) | DSS | BS³ | DSP |
|---|---|---|---|---|
| Spacer arm (Å, extended) | 6.5 | 11.4 | 11.4 | 12.0 |
| Molecular weight (g/mol) | 324.2 | 368.3 | 534.4 (sodium salt) | 404.4 |
| Backbone charge at pH 7.0 | Neutral | Neutral | Dianionic (sulfonate) | Neutral |
| Cleavable | No (stable ether) | No | No | Yes (disulfide, reductant‑labile) |
| Solubility in water at 25 °C (mM) | <0.2 (neat); >10 with 5% DMF | <0.1 | >50 | <0.1 |
| Parameter | Specification | Analytical Method |
|---|---|---|
| Appearance | White to off‑white crystalline powder | Visual, against #FFFFFF reference |
| Assay (HPLC, anhydrous basis) | ≥ 98.0% | HPLC, C18, 254 nm, area normalization |
| Moisture content | ≤ 0.5% (w/w) | Karl Fischer coulometric titration |
| Free N‑hydroxysuccinimide | ≤ 1.0% | HPLC, 260 nm, external standard |
| Solubility in DMF (clear solution) | Pass at 200 mg/mL | Dissolution in anhydrous DMF, visual inspection |
| Melting / decomposition range | 118–124 °C (dec.) | DSC, 10 °C/min under N₂ |